Calypte und die Zeit nach AIDS2004 in Bangkok

Seite 5 von 203
neuester Beitrag: 19.01.06 14:27
eröffnet am: 05.07.04 15:03 von: Kade_I Anzahl Beiträge: 5057
neuester Beitrag: 19.01.06 14:27 von: Der_wahre_. Leser gesamt: 189477
davon Heute: 15
bewertet mit 0 Sternen

Seite: Zurück 1 | 2 | 3 | 4 |
| 6 | 7 | 8 | 9 | ... | 203  Weiter  

09.07.04 18:25

2202 Postings, 7561 Tage Kade_IJetzt gehts mit wenig Vol wieder runter ! RT 0,69! o. T.

09.07.04 18:52

2202 Postings, 7561 Tage Kade_IInstitutionelle ?! Sensationell große Blöcke

wurden gerade gehandelt ! Aber RT leider bei 0,685. Ich denke wir schließen heute trotzdem noch bei ca. 0,75 $.

Blocktrades in Stück: 92.500, 200.000, 397.500, ...
Alles innerhalb von 2,5 Minuten !
What´s going on ?  

09.07.04 18:55

32217 Postings, 7988 Tage Börsenfan@werweiß

na ob die klare Kraftbrühe mal nicht versalzen wird ? Bei 80 Cent wird Caly heute wohl kaum schließen, da fehlen nun mal News.  

09.07.04 19:15

5414 Postings, 8893 Tage Biomedi@kade: Warum fragst Du? Bist Du in Bombay? o. T.

09.07.04 19:24

2202 Postings, 7561 Tage Kade_INur so Biomedi - Du warst doch da vor n paar

Wochen. Find ich geil, ich liebe asiatische Metropolen !

Grüße  

09.07.04 19:27

5414 Postings, 8893 Tage BiomediNa ja Kade; meine Mutter liegt im Sterben...

Reisen ist derzeit nicht Hauptthema fuer mich. Aber ich fahre nach Athen zu den olymp. Spielen ab 17. August  

09.07.04 20:04

2202 Postings, 7561 Tage Kade_IDas tut mir Leid, Biomedi o. T.

09.07.04 20:30

1963 Postings, 7695 Tage LuckyStrike mir auch Bio..versuche trotzdem

wieder euch auf Caly aufmerksam zu machen um  euch auf andere Ä_Gedanken zu bringen

Der Tag , der Handel ist noch nicht zu ende

Go 'Caly auf gehts mit dir!!!!!!!!!!!!!!!!!!!!!!  

09.07.04 20:31

1145 Postings, 7462 Tage Brokersince1994Der Phönix aus der Asche

Gefreut haben wir uns ja schon ein kleinwenig, dass wir unser Sorgenkind Calypte nicht vorschnell aufgegeben haben, fachliche Einschätzungen setzen sich doch sehr oft durch. So langsam wird aber sogar uns angesichts der nicht kommen wollenden guten Nachrichten um Calypte Biomedical (OTC Bulletin Board: CYPT) etwas unheimlich.
Ich denke doch, entspannt sollten wir alle darauf warten ...

Ich warte seit Monaten auf dieses Ereigniss.. Unser Geduld und Treue wird sich auszahlen...

Gruß

C.O
 

09.07.04 20:42

1145 Postings, 7462 Tage Brokersince1994News

Am Wochenende werden die ersten News kommen.. Mit den News zum Tehema Rapid werden die ersten Brocken in unser Depot fallen.....    :)

Gruß

C.O  

09.07.04 20:46

2202 Postings, 7561 Tage Kade_INeues Filling !



Form 424B3CALYPTE BIOMEDICAL CORP - CYPTFiled: July 09, 2004 (period: )Form of prospectus reflecting facts events constituting substantive change from last form





                                               Filed Pursuant to Rule 424(b)(3)
                                                 Registration Number 333-116491

                      [LOGO CALYPTE BIOMEDICAL CORPORATION]

                                  PROSPECTUS

                        CALYPTE BIOMEDICAL CORPORATION

              83,056,050 Shares of Common Stock, $0.03 Par Value

o     This  Prospectus  relates to the resale of our common stock by the selling
     security  holders,  all of whom  were  issued  securities  pursuant  to an
     exemption under  Regulation S, except for the selling  security holders in
     the May 2004 PIPE who were  issued  securities  pursuant  to an  exemption
     under Regulation D, of up to:

     o     3,088,554  shares of our  common  stock  that have  previously  been
           issued to  certain  selling  security  holders  as a result of their
           conversions of $3,232,000 aggregate original principal amount of our
           8% secured convertible notes, plus interest and liquidated damages;

     o     4,725,414 shares of our common stock,  including 563,538 shares that
           may be issued upon the conversion of the remaining $91,597 aggregate
           principal  amount  of  our  10%  convertible  debentures,  including
           accrued  interest,  extension fees and other amounts,  and 4,161,876
           shares that have been previously issued to a selling security holder
           upon  the  conversion  of  $1,100,072  principal  amount  of our 10%
           convertible   debentures,   plus  accrued  interest  and  liquidated
           damages;

     o     10,351,061 shares of our common stock, including 682,646 shares that
           may be issued upon the conversion of the remaining $66,113 aggregate
           principal amount of our 12% convertible debentures including accrued
           interest  and  other   amounts,   100,000  shares  of  common  stock
           underlying  warrants issued as part of the  consideration  for a 12%
           convertible debenture  transaction,  and 9,568,415 shares previously
           issued to certain selling security holders upon their conversions of
           $1,933,887   aggregate  principal  amount  of  our  12%  convertible
           debentures, plus accrued interest and liquidated damages;

     o     28,333,333  shares of our  common  stock that have  previously  been
           issued to a selling  security holder in connection with a $2,500,000
           PIPE   transaction  at  $0.30  per  share  and  a  $10,000,000  PIPE
           transaction at $0.50 per share;

     o     3,265,188  shares of our common stock,  including  2,569,727  shares
           that have previously been issued to certain selling security holders
           in connection  with  agreements in which we have obtained  goods and
           services in return for the  issuance of shares of our common  stock,
           and 695,461 shares underlying  warrants or other agreements  between
           us and certain selling  security holders in connection with which we
           have obtained goods and services;

     o     1,275,000 shares of our common stock  underlying  warrants issued in
           connection   with  a  $10,000,000  5%  Promissory   Note  Commitment
           Agreement and subsequent amendments thereof; and

     o     32,017,500 shares of our common stock,  including  23,250,000 shares
           that have been  previously  issued to  selling  security  holders in
           connection with a $9,300,000 May 2004 PIPE  transaction at $0.40 per
           share and an  additional  8,767,500  shares  underlying  warrants to
           purchase our common  stock at $0.50 per share issued in  conjunction
           therewith.

o     We will not receive any proceeds  from the sale of these  shares.  We will
     receive  proceeds  from the exercise of warrants  issued to certain of the
     selling  stockholders.  Any  proceeds  received  will be used for  general
     corporate purposes.

o     The  subscribers  (as detailed  below) may be deemed to be  "underwriters"
     within  the  meaning  of  the  Securities  Act of  1933,  as  amended,  in
     connection with their sales.

o     Our common stock is traded on the  Over-the-Counter  Bulletin  Board under
     the symbol  "CYPT." The last reported  sales price for our common stock on
     June 30, 2004 was $0..62 per share.

                THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK.

                   SEE " RISK FACTORS" BEGINNING ON PAGE 5.

         We may amend or supplement this Prospectus from time to time
       by filing amendments or supplements as required. You should read
            the entire Prospectus and any amendments or supplements
              carefully before you make your investment decision.

Neither  the  Securities  and  Exchange  Commission  nor  any  state  securities
commission has approved or disapproved of these securities or determined if this
Prospectus  is truthful or  complete.  Any  representation  to the contrary is a
criminal offense.

                 The date of this Prospectus is July 9, 2004.






                               TABLE OF CONTENTS


                                                                         PAGE
                                                                         ----
PART I.  INFORMATION REQUIRED IN PROSPECTUS

Where You Can Find More Information                                        1

The Company                                                                2

The Offering, including Use of Proceeds and
 Determination of Offering Price                                          4

Risk Factors                                                               5

Summary of Financings May 2002 to June 10, 2004                           18

Dilution                                                                  26

Selling Security Holders                                                  27

Plan of Distribution                                                      33

Legal Proceedings                                                         34

Directors, Executive Officers, Promoters and Control Persons              35

Security Ownership of Certain Beneficial Owners and Management            40

Description of the Securities                                             41

Disclosure of Commission Position on Indemnification
 for Securities Act Liabilities                                          52

Description of Business                                                   53

Management's Discussion and Analysis                                      71

Description of Property                                                   89

Certain Relationships and Related Transactions                            89

Market for Common Stock and Related Stockholder Matters                   90

Executive Compensation                                                    93

Financial Statements                                                     101

Changes in and Disagreements with Accountants on Accounting
 and Financial Disclosure                                               101

Interest of Named Experts and Counsel                                    103

Index to Consolidated Financial Statements                               F-1








                      WHERE YOU CAN FIND MORE INFORMATION

We file  annual,  quarterly  and special  reports,  proxy  statements  and other
information with the Securities and Exchange  Commission.  You may read and copy
any document we file at the SEC's public  reference  rooms in Washington,  D.C.,
New York, New York and Chicago,  Illinois. Please call the SEC at 1-800-SEC-0330
for further  information on the public reference rooms. Our SEC filings are also
available to the public at the SEC's web site at  http://www.sec.gov  and at our
website at http://www.calypte.com.

A copy of our Annual Report on Form 10-KSB for the year ended  December 31, 2003
is included with this Prospectus. You may request another copy of the 10-KSB, at
no cost, by writing or telephoning us at the following address:

                        Calypte Biomedical Corporation
                         5000 Hopyard Road, Suite 480
                         Pleasanton, California 94588
                             Attention: President
                          Telephone: (925) 730-7200.

You should rely only on  information  provided in this  Prospectus.  We have not
authorized anyone else to provide you with different information.

From time to time,  information we provide or statements  made by our directors,
officers  or  employees  may  constitute  "forward-looking"  statements  and are
subject  to  numerous  risks  and  uncertainties.  Any  statements  made in this
Prospectus,  including any statements incorporated herein by reference, that are
not statements of historical fact are forward-looking statements (including, but
not limited to,  statements  concerning  the  characteristics  and growth of our
market  and  customers,  our  objectives  and plans for  future  operations  and
products  and  our  liquidity  and  capital  resources).   Such  forward-looking
statements are based on current  expectations  and are subject to  uncertainties
and other  factors  which may involve  known and unknown  risks that could cause
actual  results of  operations  to differ  materially  from those  projected  or
implied. Further, certain forward-looking  statements are based upon assumptions
about future events which may not prove to be accurate.  Risks and uncertainties
inherent in forward looking statements include, but are not limited to:

o     fluctuations in our operating results;

o     announcements of technological innovations or new products which we or our
     competitors make;

o     FDA and international regulatory actions;

o     developments with respect to patents or proprietary rights;

o     changes in stock market analysts' recommendations regarding Calypte, other
     medical products companies or the medical product industry generally;

o     changes in domestic or  international  conditions  beyond our control that
     may  disrupt  our or our  customers'  or  distributors'  ability  to  meet
     contractual obligations;

o     changes in health care policy in the United States or abroad;

o     our ability to obtain  additional  financing as necessary to fund both our
     long-and short-term business plans;

o     fluctuations in market demand for and supply of our products;

o     public  concern as to the safety of products that we or others develop and
     public concern regarding HIV and AIDS;

o     availability of reimbursement  for use of our products from private health
     insurers,   governmental  health  administration   authorities  and  other
     third-party payors; and

o     price and volume  fluctuations  in the stock  market at large which do not
     relate to our operating performance.

For a further  discussion of these and other significant  factors to consider in
connection  with  forward-looking   statements,   see  the  discussion  in  this
Prospectus under the heading "RISK FACTORS".


                                      1






                                  THE COMPANY

Calypte   Biomedical   Corporation   ("Calypte"  or  the  "Company")   develops,
manufactures  and markets in vitro  diagnostic tests primarily for the detection
of antibodies  to the Human  Immunodeficiency  Virus ("HIV") and other  sexually
transmitted and infectious  diseases.  We have historically focused our business
on urine-based  screening and  supplemental  tests for use in  laboratories.  By
integrating  several proprietary  technologies,  we developed urine HIV antibody
tests, the Calypte  urine-based enzyme immunoassay  ("EIA") HIV Type 1 ("HIV-1")
screening test and the Cambridge Biotech  urine-based HIV-1 western blot ("Urine
Western Blot")  supplemental  test. We also manufacture and market the Cambridge
Biotech  serum-based  western blot ("Serum Western Blot")  supplemental test for
detecting HIV-1 antibodies in serum.  Our revenues are currently  generated from
sales of these  three  products,  which we refer to  collectively  as our "ELISA
tests." The ELISA tests are manufactured in formats that make them most suitable
for high-volume laboratory settings.

We are the only company with Food and Drug  Administration  ("FDA") approval for
the  marketing  and sale of  urine-based  HIV-1  antibody  tests.  Our EIA HIV-1
screening test received FDA approval for use in laboratories in August 1996. Our
Urine  Western Blot  supplemental  test  received FDA approval in May 1998.  Our
urine-based ELISA tests together,  with their screening and confirmatory testing
components, are the only complete FDA approved urine-based HIV testing method.

Our  business is also  involved in  developing  new test  products for the rapid
detection  of HIV-1 and HIV Type 2, a second  type of HIV  ("HIV-2"),  and other
infectious  diseases.  In  November  2003,  we filed an  Investigational  Device
Exemption  ("IDE")  with  the FDA  announcing  our  intent  to  develop  a rapid
serum-based HIV screening test. Rapid tests provide test results in less than 20
minutes and are particularly suitable for point-of-care  testing,  especially in
lesser  developed  countries  which lack the medical  infrastructure  to support
laboratory  based testing.  We are currently  developing  serum- urine- and oral
fluid-based  HIV-1 and HIV-2 rapid tests and  anticipate  that our primary focus
for the current and longer-term future will be the development,  manufacture and
sale of our rapid test products, both internationally and domestically.

We were  incorporated  in California in 1989 and  reincorporated  in Delaware in
1996 at the time of our initial public  offering.  In December 1998, we acquired
certain  assets  from  Cambridge  Biotech  Corporation,  an entity  now owned by
bioMerieux,  Inc.  The  acquisition  included  the Urine  Western Blot and Serum
Western Blot supplemental tests and leasehold rights to the Rockville,  Maryland
manufacturing facility.

We are  headquartered  at 5000 Hopyard Road, Suite 480,  Pleasanton,  California
94588,  telephone  number (925)  730-7200.  During June 2004,  we relocated  our
headquarters to this location from our previous office and manufacturing site in
Alameda,  California.  Our  manufacturing  facility  is  located  in  Rockville,
Maryland.  Historically, our Alameda facility had manufactured our EIA screening
test and the Rockville  facility  manufactured  our Urine and Serum Western Blot
tests.  However,  we are  currently  consolidating  our  domestic  manufacturing
operations by moving all manufacturing to our Rockville facility.  We closed the
Alameda facility effective June 30, 2004, when the lease expired.  As of July 2,
2004,  following  the  cessation  of  manufacturing  operations  at our  Alameda
facility, we had approximately 50 full-time and temporary employees.

To successfully  implement our business plans, we must obtain  sustainable  cash
flow and  profitability.  Our future  liquidity  and capital  requirements  will
depend on numerous factors,  including successful  completion of the development
of our new rapid tests,  acquisition  and  protection of  intellectual  property
rights,  costs of developing our new products,  ability to transfer  technology,
set up  manufacturing  and obtain  regulatory  approvals of our new rapid tests,
market  acceptance  of all our products,  competing  products in our current and
anticipated  markets,  actions  by the FDA and  other  international  regulatory
bodies, and the ability to raise additional capital in a timely manner.

Since  December 31, 2003, we have entered into new financing  arrangements  that
management  believes  will be  adequate to sustain  our  operations  at expected
levels through 2004. In May 2004, we completed a private placement of our common
stock with 7 accredited  investors  and  received net proceeds of  approximately
$8.8  million.  Additionally,  in May 2004 Marr  Technologies  BV,  our  largest
stockholder  and a  participant  in the  private  placement,  agreed  to  extend
$5,000,000  of our  borrowing  availability  under the terms of the Marr  Credit
Facility  through  December  31, 2004.  If,  however,  sufficient  funds are not
available  to fund our  operations  in 2005 or  beyond,  we may need to  arrange
additional financing or make other arrangements.  There can be no assurance that
additional  financing,  if and as  necessary,  would be  available  or, if it is
available,  that it would be on  acceptable  terms.  The terms of an  additional
financing could involve a change of control and/or require stockholder  approval
or could potentially trigger anti-dilution protection clauses that are contained
in  existing  financing  agreements.  We would or might be  required to consider
strategic  opportunities,  such  as  a  merger,  consolidation,  sale  or  other
comparable transactions, to sustain our operations. We do not currently have any
agreements  in place with  respect to any such new  strategic  opportunity,  and
there can be no assurance that any such opportunities will be available to us on
acceptable  terms, or at all. If additional  financing is not available when and
if required or is not  available  on  acceptable  terms,  or if we are unable to
arrange a suitable strategic  opportunity,  we will be in significant  financial
jeopardy and may be unable to continue our operations at current  levels,  or at
all.


                                      2





USE OF FORM SB-2 REGISTRATION STATEMENT

We were contacted by the San Francisco District Office of the SEC on October 28,
2003 and advised of an informal inquiry being conducted by the enforcement staff
of the SEC regarding the Company.  The staff has requested,  among other things,
documents  related to certain  press  releases  we issued.  We have  voluntarily
provided the information  sought by the SEC and are cooperating  with the SEC in
connection with its informal inquiry. Independently,  the Audit Committee of our
Board of Directors has  investigated  the matter and retained outside counsel to
assist  in its  investigation  by  reviewing  the  press  releases  and  related
information  that were the subject matter of the SEC's informal  inquiry letter.
The Audit Committee has completed its  investigation and reported the results of
its  investigation  and  associated  recommendations  to the Board of Directors.
Counsel for the Audit  Committee  advised the Audit  Committee  and the Board of
Directors  that the  results of their  investigation,  interviews  and review of
documents provided in response to the SEC's informal inquiry letter indicated no
evidence of management  malfeasance  with respect to its inquiry.  While the SEC
has advised us that the inquiry  should not be construed as an indication by the
SEC or its staff that any violation of law has occurred,  we informed our former
independent  auditors,  KPMG LLP ("KPMG") of the inquiry,  and they  informed us
that they could not complete  their  quarterly  review of our interim  financial
statements  contained in our  Quarterly  Report on Form 10-QSB for the quarterly
period ended September 30, 2003 or audit our financial statements for our fiscal
year  ended  December  31,  2003  until  such  time as our Audit  Committee  had
completed its investigation related to the Commission's informal inquiry letter,
the same was reviewed by KPMG, and KPMG was satisfied  that, in its opinion,  an
adequate  investigation  was conducted and appropriate  conclusions were reached
and actions taken.

The interim financial  statements  contained in a Form 10-QSB are required to be
reviewed  under  Statement  of  Auditing  Standards  No.  100 ("SAS  100") by an
independent  public  accountant  pursuant to Item 310(b) of  Regulation  S-B. We
filed our Form 10-QSB for the quarterly  period ended  September 30, 2003 within
the time permitted,  on November 14, 2003, without KPMG having completed its SAS
100 review.  On December 23, 2003,  the Company  dismissed  KPMG as  independent
auditors for the Company,  effective  immediately.  The decision to dismiss KPMG
was recommended by the Audit Committee of the Board of Directors. As of the date
of KPMG's dismissal, KPMG had advised us that, in KPMG's opinion, the conditions
necessary  for KPMG to complete  its review had not yet been  satisfied.  At the
time of KPMG's dismissal,  the Audit Committee had completed its  investigation,
had reported the results of its investigation and associated  recommendations to
the  Board  of  Directors,   and  the  Board  of  Directors  had  approved  such
recommendations.  In addition, at such time, counsel for the Audit Committee had
advised us that it had commenced to provide  information to KPMG  concerning the
investigation  conducted,  the conclusions  reached and the actions taken by the
Company.

On December  24,  2003,  upon  approval of the Audit  Committee  of the Board of
Directors,  we engaged Odenberg Ullakko Muranishi & Co. LLP ("OUM") to audit the
consolidated  financial  statements  of the  Company  for  the two  years  ended
December 31, 2003 and 2002 and to review the interim financial statements of the
Company  contained  in its  amended  Quarterly  Report  on Form  10-QSB  for the
quarterly  period ended  September  30, 2003.  OUM  completed its SAS 100 review
associated  with  the  Form  10-QSB/A  (No.1)  for the  quarterly  period  ended
September 30, 2003 that we filed on January 29, 2004.

Although we have filed an amended  10-QSB on which OUM has  completed an SAS 100
review, the staff of the SEC has taken the position that our initial Form 10-QSB
was deficient  because the required  review was not completed on a timely basis.
That  means that we are viewed as not being  current  in our  filings  under the
Securities  Exchange  Act of 1934.  Accordingly,  having been  determined  to be
deficient in our periodic filings,  we are,  therefore,  ineligible to use Forms
S-2  or S-3  to  register  securities  until  all  required  reports  under  the
Securities  Exchange  Act of 1934  have  been  timely  filed  for the 12  months
following January 29, 2004. We are currently  eligible to use either Form S-1 or
SB-2 to satisfy our obligations under the registration rights agreements we have
entered into with respect to various financing  arrangements and we have elected
to use Form SB-2 to register the subject shares of our common stock for resale.


                                      3





                                 THE OFFERING

COMMON STOCK, $0.03 par value
per share ("Common Stock"),
outstanding as of June 30, 2004:                163,997,333 shares

SHARES OFFERED BY SELLING
SECURITY HOLDERS                                83,056,050   shares,   of  which
                                               70,971,905   shares   have  been
                                               issued   to   selling   security
                                               holders and are  included in our
                                               outstanding shares.

RISK FACTORS                                    The shares involve a high degree
                                               of   risk.    Investors   should
                                               carefully      consider      the
                                               information   set  forth   under
                                               "RISK FACTORS" beginning on page
                                               5.

USE OF PROCEEDS                                 We will not receive any proceeds
                                               from  the sale of  common  stock
                                               offered  through this prospectus
                                               by the selling shareholders.  To
                                               date,  we  have  received  gross
                                               amounts of  $3,125,000  from the
                                               8% convertible  notes;  $400,000
                                               from the 2002  PIPE at $1.50 per
                                               share;   $200,000  from  the  8%
                                               convertible debentures; $150,000
                                               from the 10% convertible  notes;
                                               $1,950,000    from    the    10%
                                               convertible          debentures;
                                               $2,600,000    from    the    12%
                                               convertible          debentures;
                                               $2,500,000  from the  2003  Marr
                                               PIPE   at   $0.30   per   share,
                                               $10,000,000  from the 2003  Marr
                                               PIPE  at  $0.50  per  share  and
                                               $9,300,000  from  the  May  2004
                                               PIPE at  $0.40  per  share.  All
                                               proceeds from the aforementioned
                                               financings  have been or will be
                                               used   for   general   corporate
                                               purposes,      including     the
                                               commercialization  of our  rapid
                                               tests for HIV-1/2 diagnosis that
                                               are currently under development.
                                               We are  registering  the  shares
                                               for   re-sale  to  provide   the
                                               selling shareholders with freely
                                               tradable     securities.     The
                                               registration   of  these  shares
                                               does not  necessarily  mean that
                                               any  of  these  shares  will  be
                                               offered  or sold by the  selling
                                               shareholders.  All proceeds from
                                               the sale of  shares  sold  under
                                               this  prospectus  will go to the
                                               selling shareholders.

                                               We may receive proceeds from the
                                               selling  shareholders'  exercise
                                               of  warrants  or  options.  Such
                                               proceeds,  if any,  will be used
                                               for  working  capital  and other
                                               corporate   purposes   as  noted
                                               above. However, warrants held by
                                               certain selling shareholders may
                                               be exercised  through a cashless
                                               exercise        in       certain
                                               circumstances      while     the
                                               underlying       shares      are
                                               unregistered,  in which event we
                                               would not receive  any  proceeds
                                               from the exercise.

DETERMINATION OF OFFERING PRICE                 This prospectus may be used from
                                               time  to  time  by  the  selling
                                               shareholders   who   offer   the
                                               common  stock  in   transactions
                                               (which   may    include    block
                                               transactions)    at   prevailing
                                               market  prices  at the  time  of
                                               sale,  at prices  related to the
                                               prevailing  market prices, or at
                                               other  negotiated   prices.  The
                                               selling  shareholders  will  act
                                               independently in determining the
                                               offering price of each sale.

OVER-THE-COUNTER BULLETIN
 BOARD TRADING SYMBOL                          CYPT


                                      4






                          FORWARD-LOOKING INFORMATION

When used in this prospectus, the words "believes," "plans,""anticipates," "will
likely result," "will continue,"  "projects," "expects," and similar expressions
are intended to identify "forward-looking  statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements are subject to
certain risks and  uncertainties,  including  those risks defined  above,  which
could cause actual results to differ materially from those projected.

We  caution  readers  not  to  place  undue  reliance  on  any   forward-looking
statements, which are based on certain assumptions and expectations which may or
may not be valid or actually occur,  and which involve certain risks,  including
these risks  defined  below.  Sales and other  revenues may not commence  and/or
continue as  anticipated  due to delays or  otherwise.  As a result,  our actual
results for future  periods could differ  materially  from those  anticipated or
projected.

                                 RISK FACTORS

In addition to the other information in this Prospectus,  Calypte has identified
a number of risk factors that the Company faces.  These  factors,  among others,
may cause actual results,  events or performance to differ materially from those
expressed in any forward-looking  statements made in this Prospectus or in other
filings with the  Securities  and Exchange  Commission  or in press  releases or
other public  disclosures.  Investors  should be aware of the existence of these
factors and should  consider them  carefully in evaluating  our business  before
purchasing the shares offered in this Prospectus.

    RISK RELATED TO AN INFORMAL SECURITIES AND EXCHANGE COMMISSION INQUIRY

The SEC May Not Have Completed Its Informal Inquiry,  and We May Be Subject to a
Further Investigation.

We were contacted by the San Francisco District Office of the SEC on October 28,
2003 and  advised  that there was an informal  inquiry  being  conducted  by the
enforcement  staff of the SEC  regarding the Company.  The staff has  requested,
among other things,  documents  related to certain press releases  issued by the
Company.  The SEC has advised us that the inquiry  should not be construed as an
indication by the SEC or its staff that any violation of law has occurred and we
have  voluntarily  cooperated  with the SEC and have taken part in interviews as
well as provided the SEC with all  documents  requested.  Separately,  our Audit
Committee  retained  independent  counsel to investigate the matter addressed in
the SEC's informal inquiry,  and the Committee's  counsel  determined that there
was no evidence of management  malfeasance,  however, there is no assurance that
the SEC  will not  continue  to  pursue  the  inquiry,  or that the SEC will not
commence a formal investigation, or that there will not be sanctions against the
Company or its officers or directors.

                   RISKS RELATED TO OUR FINANCIAL CONDITION

If We are Unable to Obtain Additional Financing When and If Required We May Have
to  Significantly  Curtail the Scope of Our  Operations  and Alter Our  Business
Model.

We believe that the aggregate  $8.8 million net proceeds of our May 2004 private
placement and the extension through December 31, 2004 of $5,000,000 of borrowing
capability  under the terms of the amended Marr Credit Facility will be adequate
to sustain our operations at expected levels through 2004.  There can,  however,
be no assurance that such resources will be adequate.  Further,  there can be no
assurance  that we will be able to  achieve  expanded  acceptance  of or realize
significant  revenues from our current or potential new products,  including our
rapid tests, or that we will achieve significant  improvements in the efficiency
of our manufacturing  processes. In addition, there is no assurance that we will
achieve or sustain  profitability  or positive cash flows in the future.  In the
absence  of  adequate  resources  from  current  working  capital  and  existing
financing,  we would need to raise additional capital to sustain our operations.
In that case, we would or might be required to consider strategic opportunities,
including  merger,  consolidation,  sale or  other  comparable  transaction,  to
sustain our  operations.  We do not currently  have any agreements in place with
respect to any such  strategic  opportunity,  and there can be no assurance that
any such opportunity will be available to us on acceptable  terms, or at all. If
additional financing is not available to us when required or is not available to
us on  acceptable  terms,  or we are  unable  to  arrange a  suitable  strategic
opportunity,  we will be in significant  financial jeopardy and we may be unable
to  continue  our  operations  at  current  levels,  or at all.  The  terms of a
subsequent  financing  may  involve a change  of  control,  require  stockholder
approval,  and/or trigger anti-dilution protection clauses contained in existing
financing  agreements that would result in substantial  dilution to our existing
stockholders  or might  require  us to pledge  the  rights to our  products  for
collateral security for the issuance of a convertible debt security.


                                      5





Certain  Prospective  Investors  Were Unable to Participate in the May 2004 PIPE
Financing and We May Not Be Able to Successfully Accommodate Them.

We raised the sum of  $9,300,000  through the sale of  23,500,000  shares of our
common stock to accredited  investors at $0.40 per share, and issued warrants to
purchase 8,767,500 shares of our common stock at $0.50 per share in our May 2004
PIPE which closed as of May 31, 2004. The shares of common stock are included in
this registration statement.

Certain  prospective  investors  of one of our finders  who had been  discussing
possible  participation of approximately  $1.5 million in the May 2004 PIPE were
unable to do so for timing and other reasons.  Although we desire to accommodate
these prospective investors, we must complete any such transaction in accordance
with all applicable securities rules and regulations. If we are unable to do so,
we may be unable to accept  this  potential  investment  at this  time,  and the
finder and the prospective investors,  or a portion thereof, may choose to bring
certain  actions  against us. While we would dispute and/or oppose such actions,
should the prospective  investors prevail, we may be required to pay damages and
other possible penalties.

Our Financial  Condition has  Adversely  Affected Our Ability to Pay  Suppliers,
Service  Providers  and  Licensors  on a Timely Basis Which May  Jeopardize  Our
Ability to Continue Our Operations and to Maintain  License Rights  Necessary to
Continue Shipments and Sales of Our Products.

As of March 31, 2004 our accounts  payable  totaled $2.0 million,  of which $1.5
million  was  over  sixty  days  old.  We  currently  have  primarily  cash-only
arrangements  with suppliers and certain  arrangements  require that we pay down
certain outstanding  amounts due when we make a current payment.  These past due
payments  vary  monthly   depending  on  the  items  purchased  and  range  from
approximately  $50,000  to  $200,000  per  month.  As of March 31,  2004 we have
accrued an aggregate of  approximately  $551,000 in royalty  obligations  to our
patent licensors,  of which  approximately  $387,000 were past due. The licenses
attributable to past due royalty payments relate to technology  utilized in both
our urine EIA screening test and our supplemental urine and serum tests. Because
of the  interdependence  of the screening and supplemental  tests in our testing
algorithm,  the  inability  to use any one of the  patents  could  result in the
disruption of the revenue stream from all of our products. While at this time we
are current  with our payment  plans for past-due  amounts,  if we are unable to
maintain  sufficient  working capital,  our ability to make payments on past due
negotiated royalty obligations,  make timely payments to our critical suppliers,
service providers and to licensors of intellectual property used in our products
will be  jeopardized  and we may be  unable  to  obtain  critical  supplies  and
services and to maintain  licenses  necessary for us to continue to manufacture,
ship and sell our products. Additionally,  certain vendors and service providers
with whom we have not  currently  arranged  payment  plans have or may choose to
bring legal action against us to recover amounts they deem due and owing.  While
we may dispute these claims,  should a creditor  prevail,  we may be required to
pay all amounts due to the creditor.  If the working capital that will enable us
to make the required  payment is not available when required,  we will be placed
in  significant  financial  jeopardy  and we  may  be  unable  to  continue  our
operations at current levels, or at all.

We Have Incurred Losses in the Past and We Expect to Incur Losses in the Future.

We have incurred  losses in each year since our inception.  Our net loss for the
quarter  ended March 31, 2004 was $4.0  million and for the year ended  December
31,  2003 was $26.5  million and our  accumulated  deficit at March 31, 2004 was
$131.9 million.  We expect  operating losses to continue during 2004 and perhaps
beyond,  as we complete  the  development  and begin  commercializing  our rapid
tests, complete our manufacturing  restructuring and consolidation,  and conduct
additional research and development for product improvements and clinical trials
on potential new products.

An Economic Downturn or Terrorist Attacks May Adversely Affect Our Business.

Changes in economic conditions could adversely affect our business. For example,
in a difficult  economic  environment,  customers  may be unwilling or unable to
invest in new  diagnostic  products,  may elect to  reduce  the  amount of their
purchases or may perform less HIV testing.  A weakening  business  climate could
also  cause  longer  sales  cycles  and slower  growth,  and could  expose us to
increased  business or credit risk in dealing with customers  adversely affected
by economic conditions.


                                      6






Terrorist attacks and subsequent  governmental  responses to these attacks could
cause further  economic  instability or lead to further acts of terrorism in the
United  States and  elsewhere.  These actions could  adversely  affect  economic
conditions  outside  the  United  States  and  reduce  demand  for our  products
internationally. Terrorist attacks could also cause regulatory agencies, such as
the FDA or agencies that perform similar functions outside the United States, to
focus their  resources  on vaccines  or other  products  intended to address the
threat of  biological or chemical  warfare.  This  diversion of resources  could
delay our ability to obtain regulatory approvals required to manufacture, market
or sell our products in the United States and other countries.

               RISKS RELATED TO THE MARKET FOR OUR COMMON STOCK

The Price of Our Common Stock Has Been Highly  Volatile  Due to Several  Factors
Which Will Continue to Affect the Price of Our Stock.

Our common  stock has traded as low as $0.11 per share and as high as $1.799 per
share in the twelve  months  ended March 31,  2004.  We believe that some of the
factors leading to the volatility include:

o     price and volume  fluctuations  in the stock  market at large which do not
     relate to our operating performance;

o     fluctuations in our operating results;

o     concerns about our ability to finance our continuing operations;

o     financing  arrangements  which may require the  issuance of a  significant
     number  of  shares  in  relation   to  the  number  of  shares   currently
     outstanding;

o     announcements of technological innovations or new products which we or our
     competitors make;

o     FDA, SEC and international regulatory actions;

o     availability of reimbursement  for use of our products from private health
     insurers,   governmental  health  administration   authorities  and  other
     third-party payors;

o     developments with respect to patents or proprietary rights;

o     public concern as to the safety of products that we or others develop;

o     changes in health care policy in the United States or abroad;

o     changes in stock market analysts' recommendations regarding Calypte, other
     medical products companies or the medical product industry generally;

o     fluctuations in market demand for and supply of our products;

o     certain world conditions,  such as SARS, an economic downturn or terrorist
     attacks; and

o     anti-American sentiment in certain international markets.


Our Registration of a Significant Amount of Our Outstanding Restricted Stock and
the Availability of a Significant  Number of Shares Eligible for Future Sale May
Have a Negative Effect on the Trading Price of Our Stock.

At June 30, 2004,  investors in our common stock hold  approximately  71 million
shares of restricted stock, of which approximately 41.0 million shares relate to
acquisitions of our common stock by Marr Technologies BV ("Marr" or "MTBV"), the
provider of our current $5 million credit facility and our largest  stockholder,
through  their  participation  in  private  placements  in  2003  and  2004  and
conversion of  debentures.  Approximately  15.75 million  additional  shares are
related  to  issuances  of  restricted  shares  of our  common  stock  to  other
participants in our May 2004 private placement;  another 11.6 million shares are
related to issuances  pursuant to our  convertible  notes and  debentures and an
additional  2.6 million  shares are related to  issuances  under  contracts  and
agreements under which we have received goods and services.  Further, in the May
2004 private  placement we issued warrants that are  immediately  exercisable or
exercisable  on 61  days'  notice  that  could  result  in  the  issuance  of an
additional  8.8  million  shares.  Additionally,  we could be  required to issue
approximately  2.9 million  additional shares of our common stock if the holders
of currently  outstanding  convertible  debentures  or various  warrant  holders
elected to  convert  the  remaining  principal  and  accrued  interest  of their
debentures or exercise their outstanding warrants.  This registration  statement
includes  essentially  all of the outstanding  restricted  shares and the shares
underlying the outstanding convertible debentures and warrants. Although certain
of the Marr agreements  require that Marr hold approximately 28.2 million of its
its shares for one year following their  purchase,  essentially all of the other
shares would be freely  tradable  upon the  effectiveness  of this  registration
statement and upon conversion of the debentures or exercise of the warrants.  If
investors holding a significant number of freely tradable shares decided to sell
them in a short period of time following the  effectiveness  of the registration
statement,  such sales could  contribute  significant  downward  pressure on the
trading price of our stock.  Such sales might also inhibit our ability to obtain
future equity or equity-related financing on acceptable terms.


                                      7





From inception through June 30, 2004, we have issued approximately 164.0 million
shares of our common stock and raised  approximately $139 million.  At a Special
Meeting of  Stockholders  on February 14,  2003,  our  stockholders  approved an
increase in the number of authorized  shares of the Company's  common stock from
200  million  to 800  million.  Although  we have no plans to do so, at June 30,
2004, we have the ability,  without further  stockholder  approval,  to issue in
excess of 500  million  shares of our common  stock for  financing  or for other
purposes.  The perceived  risk of dilution  from this amount of  authorized  but
unissued  stock may cause our existing  stockholders  and other  holders to sell
their shares of stock,  which would contribute to a decrease in our stock price.
In this regard,  significant downward pressure on the trading price of our stock
may  also  cause  investors  to  engage  in short  sales,  which  would  further
contribute to significant downward pressure on the trading price of our stock.

Our Issuance of Warrants,  Options and Stock Grants to Consultants  for Services
and the  Granting of  Registration  Rights for the  Underlying  Shares of Common
Stock May Have a Negative Effect on the Trading Price of Our Common Stock.

As we  continue  to look for ways to  minimize  our use of cash while  obtaining
required services, we have issued and may continue to issue warrants and options
at or below the current  market  price or make  additional  stock bonus  grants.
During  2003,  we issued  warrants,  options  and stock  bonuses for nearly 19.8
million  shares,  including  approximately  10.0  million  shares from  employee
benefit  plans and the 2003  Non-Qualified  Stock  Option  Plan,  in payment for
consulting  services.  In the first  quarter  of 2004,  we issued  approximately
596,000 additional shares in payment for consulting services. In addition to the
potential  dilutive  effect of a large number of shares and a low exercise price
for the warrants and options,  there is the potential that a large number of the
underlying  shares may be sold on the open market at any given time, which could
place downward pressure on the trading price of our common stock.

Our Stockholders May Experience  Substantial  Dilution as a Result of Our Recent
PIPE Financing and the Anti-Dilution Provisions Contained Therein or as a Result
of Future Financings.

The current market price of our common stock and the price at which investors in
our May 2004 PIPE purchased shares of our common stock is  significantly  higher
than the book  value of our  common  stock.  Had the May 2004  PIPE  transaction
occurred as of March 31, 2004, the investors  would have invested,  net of fees,
an  amount  equal  to  approximately  $11.0  million  in  excess  of  our  total
stockholders'  equity as of that date, but would own only  approximately  15% of
our outstanding common stock.

Although we believe that we have  sufficient  funds to continue  our  operations
through 2004, we may need to arrange additional financing to fund our operations
in 2005 or thereafter. There can be no assurance that additional financing would
be  available,  or it if is  available,  that it would be on  acceptable  terms.
Additionally,  the shares  issued  pursuant to the May 2004 PIPE and the related
warrants have an anti-dilution  feature that will require us to issue additional
shares  to the PIPE  investors  and  modify  their  outstanding  warrants  if we
subsequently issue additional equity at a per share price of less than $0.40 for
a period of one year from the  closing  date,  except  under the  provisions  of
previously  outstanding  convertible  debt,  option plans,  or option or warrant
agreements. If we find it necessary to issue additional common stock to fund our
operations in the year following the May 2004 PIPE, all of our stockholders will
experience dilution; if the terms of the potential future financing require that
we issue  shares of our  common  stock at a price of less than  $0.40 per share,
holders of our common stock prior to the 2004 PIPE will  experience even greater
proportional dilution.


                                      8





Our  Common  Stock is  Subject  to the  "Penny  Stock"  Rules of the SEC and the
Trading Market In Our  Securities is Limited,  Which Makes  Transactions  in Our
Stock Cumbersome and May Reduce the Value of an Investment in Our Stock.

Shares of our common stock are "penny  stocks" as defined in the  Exchange  Act,
which are traded in the Over-The-Counter  Market on the OTC Bulletin Board. As a
result,  investors may find it more  difficult to dispose of or obtain  accurate
quotations  as to the price of the shares of the common  stock being  registered
hereby. In addition, the "penny stock" rules adopted by the Commission under the
Exchange  Act  subject  the sale of the  shares of our  common  stock to certain
regulations  which impose sales practice  requirements  on  broker/dealers.  For
example,  brokers/dealers  selling such securities  must, prior to effecting the
transaction, provide their customers with a document that discloses the risks of
investing in such securities. Included in this documents are the following:

o     the bid and offer  price  quotes  in and for the  "penny  stock",  and the
     number of shares to which the quoted prices apply.

o     the brokerage firm's compensation for the trade.

o     the  compensation  received by the  brokerage  firm's sales person for the
     trade.

In addition, the brokerage firm must send the investor:

o     a monthly  account  statement  that gives an estimate of the value of each
     "penny stock" in the investor's account.

o     a written statement of the investor's  financial  situation and investment
     goals.

Legal remedies,  which may be available to you as an investor in "penny stocks",
are as follows:

o     if "penny  stock" is sold to you in violation of your rights listed above,
     or other federal or states securities laws, you may be able to cancel your
     purchase and get your money back.

o     if the stocks are sold in a fraudulent  manner, you may be able to sue the
     persons and firms that caused the fraud for damages.

o     if you have  signed an  arbitration  agreement,  however,  you may have to
     pursue your claim through arbitration.

If the person  purchasing  the  securities  is someone  other than an accredited
investor or an established customer of the broker/dealer, the broker/dealer must
also  approve  the  potential   customer's  account  by  obtaining   information
concerning  the  customer's  financial  situation,   investment  experience  and
investment objectives.  The broker/dealer must also make a determination whether
the  transaction  is suitable  for the  customer  and whether the  customer  has
sufficient  knowledge  and  experience  in  financial  matters to be  reasonably
expected  to  be  capable  of  evaluating  the  risk  of  transactions  in  such
securities.  Accordingly,  the  Commission's  rules  may  limit  the  number  of
potential purchasers of the shares of our common stock.

Resale restrictions on transferring "penny stocks" are sometimes imposed by some
states,  which may make  transaction  in our stock more difficult and may reduce
the value of the investment.  Various state securities laws pose restrictions on
transferring  "penny stocks" and as a result,  investors in our common stock may
have the ability to sell their shares of our common stock impaired.

                         RISKS RELATED TO OUR BUSINESS

We May Be  Unsuccessful  in  Implementing  Our  Consolidation,  Development  and
Marketing Plans as Anticipated.

We are in the process of consolidating our manufacturing  facilities in a single
facility at our Rockville, Maryland location. In addition to internal validation
and comparability  studies that we conduct in conjunction with our manufacturing
consolidation,  the  FDA  must  approve  our  facility  changes  and  urine  EIA
manufacturing  operations in Rockville before we will be permitted to sell urine
EIA tests manufactured at that facility in the US. If the consolidation does not
proceed as planned,  or if the FDA does not approve the facility  changes on the
timeline  anticipated,  the  anticipated  cost  reductions  as well as increased
efficiencies may not occur.  There can be no assurance that we will successfully
complete the  development  and  commercialization  of our rapid tests  currently
under development,  or that our international  marketing efforts with respect to
these tests will result in significant additional sales. Additionally, there can
be no assurance  that we will be able to  successfully  negotiate  government or
private-sector  contracts  for  mass-testing  applications.   Consequently,  our
current financial  resources and available  financing may be inadequate,  and we
may  have to seek  additional  financing,  which  may  not be  available  on the
timetable  required  or on  acceptable  terms,  or we may  have to  curtail  our
operations, or both.


                                      9





In conjunction with our manufacturing  consolidation,  we expect that we will be
unable to  produce  our  HIV-1  Urine  EIA  product  for sale in the US until we
complete the required  validation  and  comparability  studies at our  Rockville
facility  that will be  necessary  for FDA  review and  approval.  We expect FDA
review and approval of our Rockville  facility to be completed  during the first
quarter of 2005. We believe we have manufactured  sufficient  inventories of our
HIV 1 Urine EIA test to continue to satisfy expected  customer orders during the
transition period. We have considered  historical sales levels and the length of
time  required  to  complete  the  consolidation  and  obtain  FDA  approval  in
determining  the amount of inventory  required to bridge the transition  period.
Demand could  significantly  exceed  historical  levels,  and  consolidation  of
operations or FDA approval  could take longer than  expected.  If one or more of
these events  occur,  then our  transition  inventory  may not be  sufficient to
supply customer  orders and we may lose business that we may find difficult,  or
impossible,  to replace.  Alternatively,  demand could fall significantly  below
historical levels, in which case we will have built excess inventory that we may
have to dispose of at additional cost, or at a loss.

Our Customers May Not Be Able to Satisfy Their  Contractual  Obligations  and We
May Not Be Able to Deliver Our Products as a Result of the Impact of  Conditions
Such as Severe Acute Respiratory Syndrome ("SARS") or Other World Events.

Our expected  first quarter 2003  shipment of urine HIV  screening  tests to our
distributor  in the  People's  Republic  Of China  was  delayed  until the third
quarter of 2003 in part as a result of the impact of the SARS  outbreak  in that
country.  Our distributor has reported that both potential  patients and medical
personnel were  reluctant to visit or report for work at hospitals,  clinics and
other sites for fear of contracting or spreading  SARS and,  consequently,  both
diagnostic   and   therapeutic   procedures   were   postponed.    Additionally,
governmentally-imposed  facility closures and quarantine  restrictions disrupted
the ability of the  distributor to receive and  distribute  our HIV tests.  This
situation may recur.

Our business model and future revenue forecasts call for a significant expansion
of sales in the People's  Republic of China as well as in Russia and Africa upon
successful  completion of the rapid product evaluation and regulatory  approval.
Should conditions beyond our control,  such as SARS, redirect attention from the
worldwide  HIV/AIDS  epidemic,  our customers' ability to meet their contractual
purchase obligations or our ability to supply product internationally for either
evaluation or commercial  use may prevent us from achieving the revenues we have
projected.  As a result,  we may have to seek additional  financing  beyond that
which we have projected, which may not be available on the timetable required or
on acceptable terms that are not substantially dilutive to our stockholders,  or
we may have to curtail our operations, or both.

Our Quarterly  Results May Fluctuate  Due to Certain  Regulatory,  Marketing and
Competitive Factors Over Which We Have Little or No Control.

The  factors  listed  below,  some of which we  cannot  control,  may  cause our
revenues and results of operations to fluctuate significantly:

o     actions  taken by the FDA or foreign  regulatory  bodies  relating  to our
     existing  products or products we are  currently  developing or seeking to
     develop;

o     the extent to which our  current or  proposed  new  products  gain  market
     acceptance;

o     the timing and size of purchases by our laboratory customers, distributors
     or joint venture partners;

o     introductions of alternative means for testing for HIV by competitors;

o     changes in the way requlatory authorities evaluate HIV testing,  including
     supplemental testing of the domestic blood supply; and

o     customer  concerns  about the stability of our business  which could cause
     them to seek alternatives to our product.

                                      10






Our Research,  Development and Commercialization  Efforts May Not Succeed or Our
Competitors  May  Develop  and   Commercialize   More  Effective  or  Successful
Diagnostic Products.


In order to remain competitive,  we must regularly commit substantial  resources
to research and development and the commercialization of new products.


The research and development  process  generally  takes a significant  amount of
time and money from  inception to  commercial  product  launch.  This process is
conducted in various stages.  During each stage there is a substantial risk that
we will not achieve our goals on a timely  basis,  or at all, and we may have to
abandon a product in which we have invested substantial amounts of money.


During the year ended  December  31, 2003 and in the first  quarter of 2004,  we
incurred  $1.5  million  and  $0.5  million,   respectively,   in  research  and
development  expenses.  We expect to incur even more significant  costs from our
research and development activities in the future.


A primary  focus of our  efforts  has been,  and is  expected to continue to be,
rapid HIV tests, which are currently under development. However, there can be no
assurance  that we will  succeed in our research  and  development  efforts with
respect to rapid tests or other technologies or products.


Successful  products require significant  development and investment,  including
testing,  to  demonstrate  their  cost-effectiveness  or other benefits prior to
commercialization. In addition, regulatory approval must be obtained before most
products may be sold.  Additional  development efforts on these products will be
required   before  any  regulatory   authority  will  review  them.   Regulatory
authorities  may not approve these  products for  commercial  sale. In addition,
even if a product is  developed  and all  applicable  regulatory  approvals  are
obtained,  there may be little or no market for the product, or we may be unable
to obtain  the  requisite  licenses  to sell the  product  or to  qualify  for a
government  tender,  which are often requirements in third world countries where
the  greatest  need  and  largest  market  for HIV  diagnostic  testing  exists.
Accordingly,  if we fail to  develop  commercially  successful  products,  or if
competitors  develop more  effective  products or a greater number of successful
new products,  or there are  governmental  limitations  affecting our ability to
sell our  products,  customers  may  decide  to use  products  developed  by our
competitors.  This would result in a loss of revenues and  adversely  affect our
results of operations, cash flows and business.

We Have Limited Experience Selling and Marketing Our HIV-1 Urine ELISA Tests and
No Experience Marketing a Rapid Test.

Our  urine-based  ELISA products  incorporate a unique method of determining the
presence of HIV antibodies and we have limited experience  marketing and selling
them either  domestically  or  internationally.  Further,  we have no experience
marketing  and  selling  blood or oral fluid  products.  Our  company's  success
depends upon alliances with  third-party  international  distributors  and joint
venture partners and upon our ability to penetrate  expanded markets.  There can
be no assurance that:

o     our international distributors and joint ventures will successfully market
     our products;

o     our domestic selling efforts will be effective;

o     we will obtain any expanded degree of market  acceptance among physicians,
     patients or health care payors;  or others in the medical or public health
     community, including governments and humanitarian funding sources critical
     in may  international  markets,  which are essential for acceptance of our
     products; or

o     if our  relationships  with  distributors  terminate,  we  will be able to
     establish  relationships with other distributors on satisfactory terms, if
     at all.

We have had FDA  approval  to market  our  current  urine  HIV-1  screening  and
supplemental  tests in the United States and have been marketing  these products
since  1998.  We have not yet  introduced  either an HIV-1/2  product or a rapid
point of care  test,  both of which are  necessary  in many  areas of the world.
Further,  we have not achieved  significant  market penetration with our current
ELISA tests  within  domestic or  international  markets.  A  disruption  in our
distribution,  sales or marketing  network  could reduce our sales  revenues and
cause  us to  either  cease  operations  or  expend  more  resources  on  market
penetration  efforts than are available to us without  affecting  other parts of
our business.


                                      11





We Currently  Depend Upon the Viability of Three  Primary  Products -- Our HIV-1
Urine-Based Screening Test and Our Urine and Blood Based Supplemental Tests.

Our HIV-1  urine-based  screening  test and urine and  blood-based  supplemental
tests are our  current  products.  Our sales of these  products  for the quarter
ended March,  2004 increased by 24% compared to the  comparable  period in 2003.
There can be no  assurance,  however,  that such a trend will continue and, even
with the increase,  we still incurred a loss from operations for the quarter. If
we cannot  profitably  introduce  new  products  on a timely  basis and if these
products  and our  screening  and  supplemental  tests  fail to  achieve  market
acceptance or generate significant revenues, we may have to cease operations.

We May Not be Able to Success  

09.07.04 21:51

2202 Postings, 7561 Tage Kade_IWhat the fuck ?! RT 0,62 ?! o. T.

09.07.04 21:52

1544 Postings, 7974 Tage werweißWer hat ihr den Finger auf dieser Aktie




erst stürzt der Kurs von 0,74 $ auf 0,685 $ ab, dann kauft einer in 3x200.000 Blöcke ein das sind ca. 400.000 $, und jetzt geht der Kurs nochmal runter !!!

Mehr Käufer als Verkäufer und trotzdem geht Caly runter, sehr interessant

gruß werweiß  

09.07.04 22:00

1544 Postings, 7974 Tage werweißKommt da eine Übernahme, oder was ist hier los




dieses SEC-Filing hab ich auch bei HP u. Compaq gesehen, oder ist das eine Vorbereitung für die AMEX, auf jedenfall nichts schlechtes, sonst würden alle wie blöd verkaufen !!!

Nichts ist unmöglich Calypte

gruß werweiß  

09.07.04 22:03

2202 Postings, 7561 Tage Kade_Iwerweiß: naja, seitdem das filling veröffentlicht

wurde gings aufjedenfall mächtig bergab ! Weiß auch nicht was das soll. Denke trotzdem, dass wir aus Bangkok fette News bekommen.

Grüße
Kade_I  

09.07.04 22:11

1544 Postings, 7974 Tage werweißJetzt heißt es Pokerface auf



und warten, denke mal am Montag gehn einige in Deutschland raus, deshalb drücken die jetzt in Amerika den Kurs, die wollen uns nicht den Vortritt geben, und dann ab 20.00 Uhr Montag oder Dienstag gehts ab !!!

Gruß werweiß  

09.07.04 22:11

1145 Postings, 7462 Tage Brokersince1994SEC File

Sehr seltsam die Entwicklung von CYPT . Der SEC File wahr sehr ausführlich, als würde man sagen wolle, so sah alles aus bis ....... passierte.
Lasst uns die weiteren News verfolgen, ich bin ganz Ohr  

09.07.04 22:16

1544 Postings, 7974 Tage werweißAm 6.7.2004 gabs doch schon fast die gleiche

und dann keine Reaktion, echt komisch

gruß werweiß  

09.07.04 22:16

4012 Postings, 7987 Tage standingovationuh uh hier wurde aber fett getradet 3x200k stk.

n/a  
 21:57:28  
 0.615  
 2'500  

 n/a  
 21:57:28  
 0.62  
 2'500  

 n/a  
 21:57:23  
 0.62  
 12'500  

 n/a  
 21:57:22  
 0.615  
 12'500  

 n/a  
 21:56:56  
 0.615  
 1'000  

 n/a  
 21:56:02  
 0.615  
 6'000  

 n/a  
 21:56:02  
 0.62  
 12'000  

 n/a  
 21:55:33  
 0.62  
 4'000  

 n/a  
 21:54:24  
 0.615  
 1'778  

 n/a  
 21:54:00  
 0.62  
 10'000  

 n/a  
 21:53:59  
 0.615  
 9'997  

 n/a  
 21:53:17  
 0.62  
 3'225  

 n/a  
 21:53:17  
 0.615  
 3'225  

 n/a  
 21:53:15  
 0.62  
 10'000  

 n/a  
 21:53:13  
 0.615  
 10'000  

 n/a  
 21:53:11  
 0.62  
 1'500  

 n/a  
 21:53:09  
 0.62  
 5'000  

 n/a  
 21:52:55  
 0.615  
 2'500  

 n/a  
 21:52:55  
 0.62  
 2'500  

 n/a  
 21:52:21  
 0.625  
 9'990  

 n/a  
 21:52:14  
 0.62  
 2'500  

 n/a  
 21:51:39  
 0.62  
 2'500  

 n/a  
 21:50:45  
 0.62  
 2'500  

 n/a  
 21:50:31  
 0.62  
 1'000  

 n/a  
 21:50:14  
 0.62  
 25'000  

 n/a  
 21:50:08  
 0.62  
 10'000  

 n/a  
 21:50:04  
 0.62  
 10'000  

 n/a  
 21:49:30  
 0.62  
 25'000  

 n/a  
 21:44:43  
 0.62  
 25'000  

 n/a  
 21:44:35  
 0.62  
 5'000  

 n/a  
 21:44:01  
 0.62  
 1'500  

 n/a  
 21:41:42  
 0.62  
 8'400  

 n/a  
 21:41:42  
 0.62  
 100  

 n/a  
 21:41:19  
 0.62  
 15'000  

 n/a  
 21:41:09  
 0.625  
 9'825  

 n/a  
 21:40:13  
 0.62  
 10'000  

 n/a  
 21:40:00  
 0.62  
 10'000  

 n/a  
 21:39:16  
 0.62  
 500  

 n/a  
 21:39:15  
 0.62  
 500  

 n/a  
 21:39:15  
 0.62  
 500  

 n/a  
 21:38:12  
 0.62  
 2'500  

 n/a  
 21:37:58  
 0.62  
 2'500  

 n/a  
 21:37:38  
 0.62  
 2'500  

 n/a  
 21:37:17  
 0.62  
 2'500  

 n/a  
 21:37:09  
 0.62  
 2'500  

 n/a  
 21:36:49  
 0.62  
 2'500  

 n/a  
 21:36:25  
 0.625  
 3'675  

 n/a  
 21:36:12  
 0.625  
 1'100  

 n/a  
 21:36:07  
 0.625  
 1'500  

 n/a  
 21:36:07  
 0.63  
 1'500  

 n/a  
 21:35:56  
 0.63  
 2'500  

 n/a  
 21:35:32  
 0.63  
 2'500  

 n/a  
 21:35:15  
 0.63  
 2'500  

 n/a  
 21:35:01  
 0.63  
 2'500  

 n/a  
 21:31:57  
 0.64  
 5'000  

 n/a  
 21:30:35  
 0.645  
 5'000  

 n/a  
 21:30:18  
 0.64  
 7'500  

 n/a  
 21:29:26  
 0.64  
 2'500  

 n/a  
 21:29:08  
 0.64  
 5'000  

 n/a  
 21:28:58  
 0.64  
 5'000  

 n/a  
 21:28:56  
 0.64  
 5'000  

 n/a  
 21:28:14  
 0.64  
 8'000  

 n/a  
 21:28:09  
 0.645  
 2'500  

 n/a  
 21:23:51  
 0.65  
 2'500  

 n/a  
 21:21:36  
 0.65  
 5'000  

 n/a  
 21:21:11  
 0.65  
 7'500  

 n/a  
 21:16:42  
 0.65  
 3'000  

 n/a  
 21:15:38  
 0.65  
 2'500  

 n/a  
 21:14:45  
 0.65  
 1'000  

 n/a  
 21:14:45  
 0.65  
 1'000  

 n/a  
 21:14:26  
 0.65  
 1'340  

 n/a  
 21:14:23  
 0.65  
 1'000  

 n/a  
 21:14:10  
 0.65  
 2'500  

 n/a  
 21:14:00  
 0.65  
 2'500  

 n/a  
 21:12:59  
 0.65  
 2'500  

 n/a  
 21:12:43  
 0.65  
 2'500  

 n/a  
 21:12:08  
 0.655  
 10'000  

 n/a  
 21:11:59  
 0.66  
 5'000  

 n/a  
 21:11:56  
 0.66  
 12'500  

 n/a  
 21:11:00  
 0.66  
 2'500  

 n/a  
 21:10:37  
 0.66  
 1'254  

 n/a  
 21:10:33  
 0.66  
 1'500  

 n/a  
 21:10:27  
 0.66  
 200  

 n/a  
 21:10:06  
 0.66  
 5'000  

 n/a  
 21:09:05  
 0.66  
 2'500  

 n/a  
 21:08:36  
 0.66  
 2'500  

 n/a  
 21:08:31  
 0.661  
 5'000  

 n/a  
 21:08:29  
 0.66  
 2'500  

 n/a  
 21:07:40  
 0.661  
 2'500  

 n/a  
 21:00:25  
 0.665  
 2'000  

 n/a  
 20:55:06  
 0.67  
 1'500  

 n/a  
 20:53:09  
 0.665  
 500  

 n/a  
 20:46:41  
 0.665  
 4'000  

 n/a  
 20:46:01  
 0.665  
 2'500  

 n/a  
 20:45:36  
 0.67  
 1'200  

 n/a  
 20:34:05  
 0.67  
 4'000  

 n/a  
 20:31:23  
 0.67  
 10'000  

 n/a  
 20:31:23  
 0.668  
 10'000  

 n/a  
 20:30:49  
 0.67  
 2'000  

 n/a  
 20:26:25  
 0.67  
 700  

 n/a  
 20:24:10  
 0.67  
 2'000  

 n/a  
 20:22:05  
 0.67  
 5'000  

 n/a  
 20:21:49  
 0.68  
 500  

 n/a  
 20:21:33  
 0.68  
 2'500  

 n/a  
 20:18:51  
 0.67  
 1'000  

 n/a  
 20:18:29  
 0.67  
 2'500  

 n/a  
 20:18:29  
 0.665  
 2'500  

 n/a  
 20:18:01  
 0.67  
 5'000  

 n/a  
 20:17:13  
 0.67  
 2'500  

 n/a  
 20:15:53  
 0.67  
 2'500  

 n/a  
 20:15:13  
 0.67  
 5'000  

 n/a  
 20:14:51  
 0.67  
 2'500  

 n/a  
 20:13:02  
 0.675  
 2'500  

 n/a  
 20:12:31  
 0.675  
 5'000  

 n/a  
 20:10:29  
 0.68  
 4'801  

 n/a  
 20:09:24  
 0.68  
 1'500  

 n/a  
 20:09:09  
 0.685  
 1'300  

 n/a  
 20:08:58  
 0.68  
 2'500  

 n/a  
 20:08:25  
 0.68  
 5'000  

 n/a  
 19:50:27  
 0.685  
 500  

 n/a  
 19:45:23  
 0.69  
 7'500  

 n/a  
 19:44:36  
 0.69  
 2'500  

 n/a  
 19:44:31  
 0.69  
 5'000  

 n/a  
 19:44:31  
 0.69  
 5'000  

 n/a  
 19:42:17  
 0.69  
 4'100  

 n/a  
 19:41:32  
 0.69  
 4'000  

 n/a  
 19:41:22  
 0.69  
 5'000  

 n/a  
 19:40:22  
 0.69  
 146  

 n/a  
 19:38:50  
 0.69  
 5'000  

 n/a  
 19:38:27  
 0.69  
 5'000  

 n/a  
 19:33:27  
 0.69  
 3'000  

 n/a  
 19:25:50  
 0.69  
 5'000  

 n/a  
 19:25:07  
 0.685  
 2'500  

 n/a  
 19:25:07  
 0.685  
 2'500  

 n/a  
 19:24:35  
 0.685  
 550  

 n/a  
 19:24:30  
 0.68  
 1'000  

 n/a  
 19:24:07  
 0.685  
 5'000  

 n/a  
 19:21:45  
 0.685  
 7'500  

 n/a  
 19:21:02  
 0.685  
 2'000  

 n/a  
 19:20:04  
 0.685  
 10'000  

 n/a  
 19:19:11  
 0.685  
 2'500  

 n/a  
 19:18:58  
 0.685  
 7'500  

 n/a  
 19:18:38  
 0.685  
 3'500  

 n/a  
 19:17:27  
 0.68  
 5'000  

 n/a  
 19:17:06  
 0.68  
 10'000  

 n/a  
 19:15:42  
 0.68  
 2'699  

 n/a  
 19:15:35  
 0.68  
 3'000  

 n/a  
 19:14:54  
 0.68  
 1'000  

 n/a  
 19:11:53  
 0.68  
 2'000  

 n/a  
 19:09:25  
 0.68  
 2'500  

 n/a  
 19:09:11  
 0.68  
 250  

 n/a  
 19:08:01  
 0.67  
 10'000  

 n/a  
 19:07:34  
 0.68  
 2'000  

 n/a  
 19:05:40  
 0.68  
 5'000  

 n/a  
 19:04:31  
 0.68  
 2'500  

 n/a  
 19:03:29  
 0.68  
 2'500  

 n/a  
 19:03:14  
 0.68  
 2'000  

 n/a  
 19:02:51  
 0.68  
 10'000  

 n/a  
 19:02:39  
 0.68  
 1'000  

 n/a  
 19:02:09  
 0.68  
 1'000  

 n/a  
 18:59:27  
 0.685  
 1'500  

 n/a  
 18:58:23  
 0.685  
 1'000  

 n/a  
 18:57:02  
 0.675  
 5'033  

 n/a  
 18:56:57  
 0.68  
 2'000  

 n/a  
 18:54:47  
 0.685  
 27'000  

 n/a  
 18:54:42  
 0.68  
 8'000  

 n/a  
 18:53:15  
 0.68  
 7'500  

 n/a  
 18:52:45  
 0.68  
 5'000  

 n/a  
 18:52:40  
 0.68  
 2'500  

 n/a  
 18:52:36  
 0.68  
 5'000  

 n/a  
 18:51:05  
 0.685  
 1'000  

 n/a  
 18:47:49  
 0.685  
 10'000  

 n/a  
 18:47:47  
 0.685  
 3'334  

 n/a  
 18:47:03  
 0.685  
 200'000  

 n/a  
 18:46:54  
 0.685  
 200'000  

 n/a  
 18:46:54  
 0.685  
 200'000  

09.07.04 22:18

1544 Postings, 7974 Tage werweißNehmt das zum Bettgehen mit, hehe

CYPT   Last: 0.62  Change: -0.06  -8.21%  Volume: 3,499,188   3:57pm
7/9/2004   Choose your broker  

After Hours: 0.70  +0.08  13.01%   290,600  !!!!!!!!!!!!!!!!

gruß werweiß

quelle: cbs.marketwatch.com  

09.07.04 22:22

4012 Postings, 7987 Tage standingovationes gab noch mehr werweiss noch 90'000stk *g*

After Hours:
0.66
+0.04
6.99%
370,600
4:05pm
7/9/2004  

09.07.04 22:58

2202 Postings, 7561 Tage Kade_ISorry Leute, aber es gibt bei der OTC kein

Afterhours ! Sind nur Korrekturen der Marketmakers von z.B. nicht ausgeführten Trades usw. ...  

09.07.04 23:03

4012 Postings, 7987 Tage standingovationstimmt! aber ist trotzdem lustig zu sehen

dass die letzten kurse wieder dieck im plus sind...
das lässt auf nächste woche hoffen  

09.07.04 23:18

4719 Postings, 7813 Tage leobmwhallo an alle Calys !!

schön euch zu lesen !

ich melde mich zwar nur selten - aber der Spaß geht weiter !


und die richtig guten haben ihre Euronen im Sack - das schlimme ist ////

ich gönn es Ihnen von ganzen Herzen !



Gruß
leo  

10.07.04 12:10

5414 Postings, 8893 Tage BiomediWarum ist Caly gestern so abgefallen?

Hat da jemand eine einleuchtende Erklaerung?  

Seite: Zurück 1 | 2 | 3 | 4 |
| 6 | 7 | 8 | 9 | ... | 203  Weiter  
   Antwort einfügen - nach oben